样式: 排序: IF: - GO 导出 标记为已读
-
Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical Trials Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-04-04 Silvia Zaragoza Domingo, Jordi Alonso, Montse Ferrer, Maria T. Acosta, Larry Alphs, Peter Annas, Pavel Balabanov, Anna-Karin Berger, Kim I. Bishop, Florence Butlen-Ducuing, Georg Dorffner, Chris Edgar, Manuel de Gracia Blanco, Brian Harel, John Harrison, William P. Horan, Judith Jaeger, Jan Kottner, Amy Pinkham, Daniella Tinoco, Monika Vance, Christian Yavorsky
Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate outcomes selection in early clinical trials is key to maximizing the likelihood of identifying new treatments in psychiatry and neurology. The field lacks good standards for designing outcome strategies, therefore The was formed to develop and promote good practices in outcome selection. This article describes
-
Eli Robins: The grandfather of DSM-III Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-27 Brian Kirkpatrick, Emilio Fernandez-Egea
-
How do lipids fit into the picture of severe mental health disorders? A missing pathophysiologic link or just a consequence of behavior and treatment Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-21 Eva C. Schulte, Thomas G. Schulze
-
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-19 A Guirguis, S Chiappini, GD Papanti P, R. Vickers-Smith, D Harris, JM Corkery, D Arillotta, G. Floresta, G Martinotti, F Schifano
The study addresses concerns about potential psychiatric side effects of Glucagon-like peptide-1 receptor agonists (GLP-1 RA). The aim of this work was to analyse adverse drug reports (ADRs) from the Food and Drug Administration Adverse Events Reporting System (FAERS) using metformin and orlistat as comparators. Descriptive and pharmacovigilance disproportionality analyses was performed. A total of
-
Mindfulness-based cognitive therapy neurobiology in treatment-resistant obsessive-compulsive disorder: A domain-related resting-state networks approach Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-18 Víctor De la Peña-Arteaga, Marta Cano, Daniel Porta-Casteràs, Muriel Vicent-Gil, Neus Miquel-Giner, Ignacio Martínez-Zalacaín, Lorea Mar-Barrutia, Marina López-Solà, Jessica R. Andrews-Hanna, Carles Soriano-Mas, Pino Alonso, Maria Serra-Blasco, Clara López-Solà, Narcís Cardoner
Mindfulness-based cognitive therapy (MBCT) stands out as a promising augmentation psychological therapy for patients with obsessive-compulsive disorder (OCD). To identify potential predictive and response biomarkers, this study examines the relationship between clinical domains and resting-state network connectivity in OCD patients undergoing a 3-month MBCT programme. Twelve OCD patients underwent
-
Trait anxiety is associated with attentional brain networks Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-16 Víctor De la Peña-Arteaga, Pamela Chavarría-Elizondo, Asier Juaneda-Seguí, Ignacio Martínez-Zalacaín, Pedro Morgado, José Manuel Menchón, Maria Picó-Pérez, Miquel A. Fullana, Carles Soriano-Mas
Trait anxiety is a well-established risk factor for anxiety and depressive disorders, yet its neural correlates are not clearly understood. In this study, we investigated the neural correlates of trait anxiety in a large sample ( = 179) of individuals who completed the trait and state versions of the State-Trait Anxiety Inventory and underwent resting-state functional magnetic resonance imaging. We
-
Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-15 Dongfang Wang, Johannes Schneider-Thoma, Spyridon Siafis, Mengchang Qin, Hui Wu, Yikang Zhu, John M Davis, Josef Priller, Stefan Leucht
Long-acting injectable antipsychotics (LAIs) are primarily used for relapse prevention, but in some settings and situations, they may also be useful for acute treatment of schizophrenia. We conducted a systematic review and frequentist network meta-analysis of randomized-controlled trials (RCTs), focusing on adult patients in the acute phase of schizophrenia. Interventions were risperidone, paliperidone
-
Identification and treatment of individuals with childhood-onset and early-onset schizophrenia Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-15 Christoph U. Correll, Celso Arango, Birgitte Fagerlund, Silvana Galderisi, Martien J. Kas, Stefan Leucht
Approximately 8 % of patients with schizophrenia are diagnosed before age 18, and 18 % experience their first symptoms before age 18. This narrative review explores the management of patients with early-onset schizophrenia (EOS) and childhood-onset schizophrenia (COS) from diagnosis to their transition to adult care settings. Early diagnosis of schizophrenia in children and adolescents is essential
-
Choosing lithium in the perinatal period, lower dose in the first trimester of pregnancy Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-15 Veerle Bergink
-
Assessing risk for bipolar disorder. Comments on ``Young people at risk for developing bipolar disorder: Two-year findings from the multicenter prospective, naturalistic Early-BipoLife study'' (Martini et al., 2023) Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-15 Mireia Solerdelcoll, Inmaculada Baeza, Gisela Sugranyes
-
Settling a distracted globe: An overview of psychosocial and psychotherapeutic treatment of attention-deficit/hyperactivity disorder Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-14 Xenia Gonda, Sara Balint, Janos Miklos Rethelyi, Peter Dome
While the currently prevailing theory of ADHD postulates a neurobiological background and core deficits of behavioural inhibition and executive functioning as the basis of ADHD symptoms, our current conceptualisation also acknowledges the essential contributory role of psychosocial, ecological, and cognitive factors. Considering the multifactorial background of ADHD, its treatment equally needs to
-
Antidepressants and suicide—More benefit than harm Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-14 Erkki Isometsä
-
Parvalbumin interneuron deficits in schizophrenia Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-14 Oscar Marín
Parvalbumin-expressing (PV+) interneurons represent one of the most abundant subclasses of cortical interneurons. Owing to their specific electrophysiological and synaptic properties, PV+ interneurons are essential for gating and pacing the activity of excitatory neurons. In particular, PV+ interneurons are critically involved in generating and maintaining cortical rhythms in the gamma frequency, which
-
The why and the how of transdiagnostic clinical research in youth psychiatry Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-14 Covadonga M. Díaz-Caneja, Sinan Guloksuz
-
Suicide mortality in Spain during the COVID-19 pandemic: Longitudinal analysis of sociodemographic factors Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-14 Alejandro de la Torre-Luque, Ivan Perez-Diez, Andres Pemau, Gonzalo Martinez-Ales, Guilherme Borges, Victor Perez-Sola, Jose Luis Ayuso-Mateos
The COVID-19 pandemic has compromised public health response across the globe. Several countries reported increasing number of suicides during the pandemic. This study aimed to analyze the suicide mortality series in Spain (2000-2021), with a particular interest in depicting longitudinal trends during the COVID-19 pandemic. Moreover, it intended to identify sociodemographic groups with a higher increase
-
A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-14 Brooke Manning, Amie C. Hayley, Sarah Catchlove, Con Stough, Luke A. Downey
As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine the neurocognitive effects of commonly prescribed products to ensure associated safety profiles. The present study aims to investigate the acute effects of a standard 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 mg Δ9-
-
The pros and cons of banning electronic cigarettes Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-03-14 Wim van den Brink, Jan van Amsterdam
-
Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-23 Michele Fornaro, Claudio Caiazza, Flavia Rossano, Flavia Cilmi, Michele De Prisco, Eduard Vieta, Trevor Thompson, Marco Solmi, Andre Ferrer Carvalho, Felice Iasevoli, Andrea de Bartolomeis
Sleep medications often carry residual effects potentially affecting driving safety, warranting network meta-analysis (NMA). PubMed/EMBASE/TRID/Clinicaltrials.gov/WHO-ICTRP/WebOfScience were inquired for randomized controlled trials of hypnotic driving studies in persons with insomnia and healthy subjects up to 05/28/2023, considering the vehicle's standard deviation of lateral position - SDLP (Standardized
-
Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-17 Marco Solmi, Giovanni Croatto, Michele Fornaro, Lynne Kolton Schneider, S. Christy Rohani-Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale, Jari Tiihonen, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Rene Ernst Nielsen, Joseph Firth, Paolo Fusar-Poli, Catharina Hartman, Richard I G Holt, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko
People with schizophrenia die prematurely, yet regional differences are unclear.
-
Does valerian work for insomnia? An umbrella review of the evidence Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-14 Valéria Valente, Daniela Machado, Susana Jorge, Christopher L. Drake, Daniel Ruivo Marques
Valerian is one of the most used herbal agents (phytotherapeutics) to manage sleep disturbances, in particular, sleep-onset difficulties in young adults. However, the evidence based on primary studies and systematic reviews that supports its use in this domain is weak or inconclusive. In the current study, an umbrella review was performed on the efficacy of valerian for sleep disturbances with a focus
-
Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-09 Filip Milosavljević, Prof. Espen Molden, Prof. Magnus Ingelman-Sundberg, Assoc. Prof. Marin M Jukić
The aim of the study was to assess the clinical utility of currently available pharmacogenomic (PGx) tools compared with treatment as usual (TAU), using a meta-analysis of dichotomous and continuous antidepressant efficacy and tolerability data from previously published clinical trials. MEDLINE, clinicaltrial.gov, EU Clinical Trials Register, WHO ICTRP and CENTRAL were systematically searched; of the
-
Suicidal behavior: Not just an epiphenomenon of psychiatric illness Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-07 Maria A. Oquendo, Enrique Baca-Garcia
-
Polygenic risk scores mediating functioning outcomes through cognitive and clinical features in youth at family risk and controls Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Alex G Segura, Elena de la Serna, Gisela Sugranyes, Inmaculada Baeza, Isabel Valli, Irene Martínez-Serrano, Covadonga M Díaz-Caneja, Álvaro Andreu-Bernabeu, Dolores M Moreno, Patricia Gassó, Natalia Rodríguez, Albert Martínez-Pinteño, Llucia Prohens, Carla Torrent, Clemente García-Rizo, Sergi Mas, Josefina Castro-Fornieles
Schizophrenia and bipolar disorder exhibit substantial clinical overlap, particularly in individuals at familial high risk, who frequently present sub-threshold symptoms before the onset of illness. Severe mental disorders are highly polygenic traits, but their impact on the stages preceding the manifestation of mental disorders remains relatively unexplored. Our study aimed to examine the influence
-
What is really different about older age bipolar disorder? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Annemiek Dols, Martha Sajatovic
-
Social cognition in maltreated individuals: Do type and timing of maltreatment matter? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Natalia E. Fares-Otero, Inga Schalinski
-
Impact of genetic, sociodemographic, and clinical features on antidepressant treatment trajectories in the perinatal period Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-06 Xiaoqin Liu, Nhung TH Trinh, Naomi R. Wray, Angela Lupattelli, Clara Albiñana, Esben Agerbo, Bjarni J. Vilhjálmsson, Veerle Bergink, Trine Munk-Olsen
Pregnant women on antidepressants must balance potential fetal harm with the relapse risk. While various clinical and sociodemographic factors are known to influence treatment decisions, the impact of genetic factors remains unexplored. We conducted a cohort study among 2,316 women with diagnosed affective disorders who had redeemed antidepressant prescriptions six months before pregnancy, identified
-
Clinical and electrophysiological correlates of hopelessness in the context of suicide risk✰ Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Elizabeth D. Ballard, Roshni P. Nischal, Courtney R. Burton, Deanna K. Greenstein, Grace E. Anderson, Laura R. Waldman, Carlos A. Zarate Jr, Jessica R. Gilbert
Hopelessness is a key risk factor for suicide. This analysis explored whether hopelessness indicates a recent suicide crisis state and is linked with magnetoencephalography (MEG) oscillatory power and effective connectivity differences. Change in hopelessness ratings and effective connectivity post-ketamine were also evaluated in a subsample of high-risk individuals to evaluate correlates of dynamic
-
Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Djenifer B. Kappel, Elliott Rees, Eilidh Fenner, Adrian King, John Jansen, Marinka Helthuis, Michael J. Owen, Michael C. O'Donovan, James T.R. Walters, Antonio F. Pardiñas
Clozapine is the only licensed medication for treatment-resistant schizophrenia (TRS). Few predictors for variation in response to clozapine have been identified, but clozapine metabolism is known to influence therapeutic response and adverse side effects. Here, we expand on genome-wide studies of clozapine metabolism, previously focused on common genetic variation, by analysing whole-exome sequencing
-
Choosing lithium in the perinatal period Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Alba Roca-Lecumberri, Eva Solé
-
Advancing psychiatric care: The transition from symptom-based diagnosis to personalized psychiatry Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Carlos Lopez-Jaramillo
-
Can cognition screening in the clinic aid personalised treatment in bipolar disorder? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Kamilla Woznica Miskowiak, Hanne Lie Kjærstad
-
Using digital phenotyping to classify bipolar disorder and unipolar disorder – exploratory findings using machine learning models Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Maria Faurholt-Jepsen, Darius Adam Rohani, Jonas Busk, Morten Lindberg Tønning, Mads Frost, Jakob Eyvind Bardram, Lars Vedel Kessing
The aims were to investigate 1) differences in smartphone-based data on phone usage between bipolar disorder (BD) and unipolar disorder (UD) and 2) by using machine learning models, the sensitivity, specificity, and AUC of the smartphone data in classifying BD and UD. Daily smartphone-based self-assessments of mood and same-time passively collected smartphone data on smartphone usage was available
-
Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Konstantinos N. Fountoulakis, Mauricio Tohen, Carlos A. Zarate JR.
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. Currently, only quetiapine, olanzapine-fluoxetine combination, lurasidone, cariprazine, and recently lumateperone have been FDA-approved to treat this condition. The neurobiology of bipolar depression and the possible mechanistic targets of bipolar antidepressant therapy remain elusive. The current
-
Should lithium be used in children and adolescents with bipolar disorder? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-02-03 Gonzalo Salazar de Pablo, Allan H. Young
Abstract not available
-
-
-
-
Whole-brain structural and functional neuroimaging of individuals who attempted suicide and people who did not: A systematic review and exploratory coordinate-based meta-analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2024-01-18 Nicola Meda, Alessandro Miola, Giulia Cattarinussi, Fabio Sambataro
Suicide is the cause of death of approximately 800,000 people a year. Despite the relevance of this behaviour, risk assessment tools rely on clinician experience and subjective ratings.
-
-
-
-
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-22 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B. Silva, Lucas O. Maia, Handersson Barros, Sophie Laborde, Flávia Arichelle, Sam Tullman, Natan Silva-Costa, Aline Assunção, Raissa Almeida, Érica J. Pantrigo, Raynara Bolcont, José Victor Costa-Macedo, Emerson Arcoverde, Nicole Galvão-Coelho, Draulio B. Araujo, Fernanda Palhano-Fontes
Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at investigating
-
Teratogenicity of valproate: Further reasons for action Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-21 Gerard Anmella, Eduard Vieta
Abstract not available
-
Clinical features in co-occuring obsessive-compulsive disorder and bipolar disorder: A systematic review and meta-analysis Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-20 Michele De Prisco, Cristiana Tapoi, Vincenzo Oliva, Chiara Possidente, Robertas Strumila, Christine Takami Lageborn, Lorenzo Bracco, Nicolaja Girone, Monica Macellaro, Eduard Vieta, Giovanna Fico
Obsessive-compulsive disorder (OCD) frequently co-occurs with various psychiatric conditions and may impact as many as one-fifth of individuals diagnosed with bipolar disorder (BD). Despite the expanding body of literature on the coexistence of OCD and BD, there is a notable lack of comprehensive data pertaining to the distinct features of obsessive-compulsive symptoms that define this comorbidity
-
The complex scenario behind the term antipsychotic drug Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-20 Marco A. Riva, Annamaria Cattaneo
Abstract not available
-
Duration of the psychosis prodrome and its relationship to duration of untreated psychosis across all 12 DSM-IV psychotic diagnoses: Evidence for a trans-diagnostic process associated with resilience Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-20 Nnamdi Nkire, Anthony Kinsella, Vincent Russell, John L. Waddington
While duration of the psychosis prodrome (DPP) attracts attention in relation to the developmental trajectory of psychotic illness and service models, fundamental issues endure in the context of dimensional-spectrum models of psychosis. Among 205 epidemiologically representative subjects in the Cavan-Monaghan First Episode Psychosis Study, DPP was systematically quantified and compared, for the first
-
Can antipsychotics prevent transition to psychosis in high-risk population? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-14 Pavel Mohr
Abstract not available
-
Cognitive impairment after recovery from COVID-19: Frequency, profile, and relationships with clinical and laboratory indices Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-07 Silvana Galderisi, Andrea Perrottelli, Luigi Giuliani, Maria Antonietta Pisaturo, Palmiero Monteleone, Pasquale Pagliano, Antonio Vita, Maria Lorenza Muiesan, Mario Amore, Matteo Bassetti, Alberto Siracusano, Armida Mucci, Paola Bucci, Giammarco Cascino, Stefano Barlati, Andrea Amerio, Giorgio Di Lorenzo, Cinzia Niolu, Nicola Coppola, Mario Maj
Cognitive impairment (CI) is regarded as a remarkable burden in COVID-19 survivors. Its prevalence and profile, and relationships with the disease clinical and laboratory indices, remain unclear. The present study investigated, in a large sample of patients recovered from COVID-19, the frequency of CI with both a face-to-face screening tool and comprehensive test battery (MCCB). The study also evaluated
-
The never-ending problem: Sample size matters Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-05 Michele De Prisco, Eduard Vieta
Abstract not available
-
Investigation of TRPV1 gene expression in bipolar disorder and its association with CB1 and MOR gene expression Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-12-06 Andrea Escelsior, Martino Belvederi Murri, Bruno Sterlini, Samuele Tardito, Tiziana Altosole, Anna Bovio, Beatriz Pereira da Silva, Daniela Fenoglio, Gilberto Filaci, Mario Amore, Gianluca Serafini
Abstract not available
-
A posterior-alpha ageing network is differentially associated with antidepressant effects of venlafaxine and rTMS Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-11-24 Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, but chances for remission largely decrease with each failed treatment attempt. It is therefore desirable to assign a given patient to the most promising individual treatment option as early as possible. We used a polygenic score (PGS) informed electroencephalography (EEG) data-driven approach to identify potential predictors
-
The significance of an integrated multi-omics approach in psychiatric disorders: A pharmacological perspective. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-11-15 Mojtaba Oraki Kohshour,Urs Heilbronner
-
Substance P, NPY, CCK and their receptors in five brain regions in major depressive disorder with transcriptomic analysis of locus coeruleus neurons. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-11-04 Swapnali Barde,Julio Aguila,Wen Zhong,Anna Solarz,Irene Mei,Josee Prud'homme,Miklos Palkovits,Gustavo Turecki,Jan Mulder,Mathias Uhlén,Corina Nagy,Naguib Mechawar,Eva Hedlund,Tomas Hökfelt
Major depressive disorder (MDD) is a serious disease and a burden to patients, families and society. Rodent experiments and human studies suggest that several neuropeptide systems are involved in mood regulation. The aim of this study is two-fold: (i) to monitor, with qPCR, transcript levels of the substance P/tachykinin (TAC), NPY and CCK systems in bulk samples from control and suicide subjects,
-
Infection-associated chronic disability: A transdiagnostic and translational opportunity for neuroscience Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Livia J. De Picker, Michael Berk
Abstract not available
-
Do epidemiologists choose the right tools to explore the impact of mental disorders over time? Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Mette Lise Lousdal, Oleguer Plana-Ripoll
Abstract not available
-
Methodological concerns in psychedelic research: The issues of nonequivalent psychological support and generalizability. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Richard J Zeifman,Lucas O Maia
-
Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer's disease patients. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Martien J H Kas,Niels Jongs,Maarten Mennes,Brenda W J H Penninx,Celso Arango,Nic van der Wee,Inge Winter-van Rossum,Jose Luis Ayuso-Mateos,Amy C Bilderbeck,Philippe l'Hostis,Christian F Beckmann,Gerard R Dawson,Bernd Sommer,Hugh M Marston
The current neuropsychiatric nosological categories underlie pragmatic treatment choice, regulation and clinical research but does not encompass biological rationale. However, subgroups of patients suffering from schizophrenia or Alzheimer's disease have more in common than the neuropsychiatric nature of their condition, such as the expression of social dysfunction. The PRISM project presents here
-
Unlocking the enigma: Metabolic risks of typical antipsychotics and their link to COVID-19 mortality. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Chia Siang Kow,Dinesh Sangarran Ramachandram,Syed Shahzad Hasan
-
Pharmacological anti-inflammatory treatment in children and adolescents with depressive symptoms: A systematic-review and meta-analysis. Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-10-19 Jasper Vöckel,Anna Markser,Lisa Wege,Heidrun Lioba Wunram,Christine Sigrist,Julian Koenig
Growing evidence suggests an association between inflammatory processes and depressive disorders (DD). DD typically emerge during adolescence. Treatment effects of agents with anti-inflammatory properties in youth DD have not been systematically reviewed. Here, the existing evidence on the use of anti-inflammatory drugs (including polyunsaturated fatty acids, nonsteroidal anti-inflammatory drugs, cytokine
-
Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar I disorder: Meta-analysis from four randomized, placebo-controlled maintenance studies Eur. Neuropsychopharm. (IF 5.6) Pub Date : 2023-09-27 Eduard Vieta, Sanman Ghorpade, Arunangshu Biswas, Angshuman Sarkar, Abhay Phansalkar, James Cooper
This meta-analysis investigated the efficacy, safety, and tolerability of lamotrigine versus placebo in preventing relapse and recurrence of mood episodes in women of childbearing age with bipolar I disorder. Following up to 16 weeks’ open-label lamotrigine treatment, responders were randomized to double-blind treatment, including lamotrigine 100–400 mg/day or placebo, in four trials of up to 76 weeks